Business / Finance

RSS

Stratified Medicine Scotland Innovation Centre (SMS-IC) receives funding from the Scottish Funding Council

The University of Glasgow is set to boost its contribution to global medical research and the Scottish economy following the announcement of funding to build a major research centre.

23 Apr 2013

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Aeterna Zentaris Inc. today announced that its German subsidiary has entered into binding agreements with various partners and licensees with respect to the manufacturing rights and obligations for its Cetrotide® product.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.

22 Apr 2013

Avinger and PDL BioPharma close structured financing and royalty transaction

Avinger, Inc. and PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of a structured financing and royalty transaction on April 18, 2013, in which PDL will provide Avinger with up to $40 million of mezzanine financing.

22 Apr 2013

Mirus Bio to use CSIRO's RAFT Polymerization Technology to expedite its product development efforts

CSIRO and Mirus Bio LLC are pleased to announce a new license arrangement that will enable Mirus Bio to utilize the unique characteristics of CSIRO's Reversible Addition-Fragmentation chain Transfer polymerisation technology (RAFT) to expand upon its high-end polymer development capabilities for the biotech industry.

22 Apr 2013

Bausch + Lomb agrees to commercialize Paragon BioTeck's phenylephrine in US

Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.

20 Apr 2013

Quest Diagnostics agrees to acquire Dignity Health's lab-related clinical outreach service operations

Quest Diagnostics, the world's leading provider of diagnostic information services, announced today that it has entered into a definitive agreement to acquire lab-related clinical outreach service operations of Dignity Health, a hospital system based in California.

From Quest Diagnostics 19 Apr 2013

Fully-retractable embolization coil introduced by Cook Medical

Cook Medical has launched a new fully-retractable .035 inch embolization coil, intended for peripheral arterial and venous embolization. Embolization is a nonsurgical, minimally invasive procedure performed by a physician to block or reduce blood flow in arteries and veins. Cook is showcasing the Retracta™ Detachable Embolization Coil at booth #1331 at the annual Society of Interventional Radiology (SIR) meeting.

18 Apr 2013

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

Santaris Pharma A/S, a privately held biopharmaceutical company focused on developing medicines targeted to disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid Drug Platform.

18 Apr 2013

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Vygon, a French family-run business that develops, produces and markets medical devices, including catheters and implantable ports for administering chemotherapy treatments, today announce their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.

16 Apr 2013

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Columbia Laboratories amends license, supply agreement with Merck Serono for CRINONE

Columbia Laboratories, Inc. has amended its license and supply agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for CRINONE (progesterone gel) through May 2020, representing an extension of five years beyond the current term, which was due to expire in May 2015.

10 Apr 2013

Business Network Services from Anglia Ruskin: an interview with Prof Young

The Anglia Ruskin Medtech Campus Business Network Services have been developed in partnership with Chelmsford City Council, Harlow District Council and Southend-on-Sea Borough Council as part of plans to form the largest MedTech cluster in the UK over three development sites in Essex.

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

Acadia Healthcare signs agreement to purchase two acute inpatient psychiatric facilities

Acadia Healthcare Company, Inc. today announced that it has signed a definitive purchase agreement with Ten Broeck Tampa, Inc. and Capestrano Investment Company, Inc. to purchase two acute inpatient psychiatric facilities.

5 Apr 2013

Diaverum acquires four clinics in Hamburg, Germany

Diaverum, one of the world's leading, product-independent renal care providers, has announced the major acquisition of the four clinics that make up the Alte Teichweg centre in Hamburg, Germany.

4 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Business / Finance

Stratified Medicine Scotland Innovation Centre (SMS-IC) receives funding from the Scottish Funding Council

Aeterna enters into agreements to transfer manufacturing license for Cetrotide to Merck KGaA

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Advaxis to license its ADXS-HPV product candidate to FusionVax

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Avinger and PDL BioPharma close structured financing and royalty transaction

Mirus Bio to use CSIRO's RAFT Polymerization Technology to expedite its product development efforts

Bausch + Lomb agrees to commercialize Paragon BioTeck's phenylephrine in US

Quest Diagnostics agrees to acquire Dignity Health's lab-related clinical outreach service operations

Fully-retractable embolization coil introduced by Cook Medical

Santaris Pharma, Bristol-Myers Squibb partner to develop novel medicines using LNA Drug Platform

New generation of innovative medical devices to be created by Curie-Cancer and Vygon partnership

COPD phase III study by Almirall and Forest Laboratories announces positive results

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Columbia Laboratories amends license, supply agreement with Merck Serono for CRINONE

Business Network Services from Anglia Ruskin: an interview with Prof Young

GenSight Biologics announces closing of €32 million Series A financing

Acadia Healthcare signs agreement to purchase two acute inpatient psychiatric facilities

Diaverum acquires four clinics in Hamburg, Germany

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News